Polymerase I pathway inhibitor ameliorates experimental autoimmune encephalomyelitis

Area of Science:

• Neuroimmunology
• Molecular Biology

Background:

• High throughput gene expression microarrays revealed that suppressed polymerase 1 (POL1) pathway activity correlates with a benign course in multiple sclerosis (MS).
• This observation suggests that targeting the POL1 transcription machinery could be a novel therapeutic strategy for MS.

Purpose of the Study:

• To investigate the efficacy of a specific polymerase I inhibitor (POL1-I) in ameliorating experimental autoimmune encephalomyelitis (EAE), an animal model of MS.

Main Methods:

• Female C57BL/6J mice were immunized with MOG35-55/CFA to induce EAE.
• POL1-I was administered via oral gavage at different timings and doses: from immunization to disease onset, at disease onset, or in a combined model.
• Gene expression of key POL1 pathway genes and P53-dependent apoptosis in CD4+ splenocytes were analyzed.

Main Results:

• POL1-I significantly delayed EAE onset and reduced maximal clinical scores in the immunization model.
• In the treatment model, POL1-I markedly reduced disease activity and maximal scores.
• Complete inhibition of EAE was observed in the combined model.
• POL1-I treatment decreased expression of POL1 pathway genes (LRPPRC, pre-RNA, POLR1D, RRN3) and induced P53-dependent apoptosis of CD4+ splenocytes.

Conclusions:

• Inhibition of the POL1 pathway effectively delays and suppresses EAE development in mice.
• POL1-I ameliorates established EAE, demonstrating therapeutic potential for MS treatment.
• Targeting the POL1 pathway represents a promising innovative strategy for MS therapy.